Literature DB >> 16433866

Drug safety and the media.

Patrick C Waller1, Stephen J W Evans, Keith Beard.   

Abstract

This article reviews the problems that may arise as a result of media coverage of drug safety issues. In order to promote more balanced coverage and avoid unnecessary scares, professionals working in the area of drug safety should rethink their strategies for dealing with the media.

Mesh：

Year:  2006        PMID： 16433866      PMCID： PMC1885006          DOI： 10.1111/j.1365-2125.2005.02528.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  7 in total

1.  Another media scare about MMR vaccine hits Britain.

Authors:  P Anderson
Journal:  BMJ       Date:  1999-06-12

2.  Injection of confidence. The recent controversy in the UK has led to falling MMR vaccination rates.

Authors:  Susan R Owens
Journal:  EMBO Rep       Date:  2002-05       Impact factor: 8.807

3.  Dealing with uncertainty in drug safety: lessons for the future from sertindole.

Authors:  Patrick Waller
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003-06       Impact factor: 2.890

4.  Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.

Authors:  Brian L Strom
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

5.  Medical research and the news media.

Authors:  Edward W Campion
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

6.  Human insulin and hypoglycaemia: burning issue or hot air?

Authors:  G Williams; A W Patrick
Journal:  BMJ       Date:  1992-08-08

Review 7.  The 'precautionary principle' as a guide for future drug development.

Authors:  S Alban
Journal:  Eur J Clin Invest       Date:  2005-03       Impact factor: 4.686
  7 in total
  8 in total

1.  Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies.

Authors:  Priya Bahri
Journal:  Drug Saf       Date:  2010-12-01       Impact factor: 5.606

2.  An industry perspective on the Erice declaration and risk minimisation plans.

Authors:  Simon Ingate; Deborah Tranter; Anjan Banerjee; Andrew Hobbs
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Hip fracture trends in the United States, 2002 to 2015.

Authors:  E Michael Lewiecki; N C Wright; J R Curtis; E Siris; R F Gagel; K G Saag; A J Singer; P M Steven; R A Adler
Journal:  Osteoporos Int       Date:  2017-12-27       Impact factor: 4.507

Review 4.  Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

5.  Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example.

Authors:  Florence van Hunsel; Anneke Passier; Kees van Grootheest
Journal:  Br J Clin Pharmacol       Date:  2009-02-26       Impact factor: 4.335

6.  Interrupted Time Series Analysis of Changes in Zolpidem Use Due to Media Broadcasts.

Authors:  Bo-Ram Yang; Kyu-Nam Heo; Yun Mi Yu; Ga-Bin Yeom; Hye Duck Choi; Ju-Yeun Lee; Young-Mi Ah
Journal:  Int J Environ Res Public Health       Date:  2021-05-12       Impact factor: 3.390

7.  Pharmaceutical company perspectives on current safety risk communications in Japan.

Authors:  Hisashi Urushihara; Gen Kobashi; Hideaki Masuda; Setsuko Taneichi; Michiko Yamamoto; Takeo Nakayama; Koji Kawakami; Tsutomu Matsuda; Kaori Ohta; Hiroki Sugimori
Journal:  Springerplus       Date:  2014-01-24

8.  Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands.

Authors:  Esther de Vries; Petra Denig; Sieta T de Vries; Taco B M Monster; Jacqueline G Hugtenburg; Peter G M Mol
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.